Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: Murdock Madaus Schwabe

This article was originally published in The Tan Sheet

Executive Summary

Murdock Madaus Schwabe: Structure/function statements on NaturaLife herbal products will be released "at a pace much slower than that reported" in a story that appeared in the May 22 issue of "The Tan Sheet" (pp. 11-13), the parent company states. "The Tan Sheet" had reported that NaturaLife expects approximately 50 herbal products to carry a statement by this summer. NaturaLife is currently "reviewing the DSHEA language to determine the scope of statements that can be made," Murdock Madaus Schwabe said. "Only when it is certain that all criteria for a statement of nutritional support (structure/function claim) has been met, will we market such a statement"...

Murdock Madaus Schwabe: Structure/function statements on NaturaLife herbal products will be released "at a pace much slower than that reported" in a story that appeared in the May 22 issue of "The Tan Sheet" (pp. 11-13), the parent company states. "The Tan Sheet" had reported that NaturaLife expects approximately 50 herbal products to carry a statement by this summer. NaturaLife is currently "reviewing the DSHEA language to determine the scope of statements that can be made," Murdock Madaus Schwabe said. "Only when it is certain that all criteria for a statement of nutritional support (structure/function claim) has been met, will we market such a statement"....

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS083921

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel